Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis
- PMID: 2206784
- PMCID: PMC1368221
- DOI: 10.1111/j.1365-2125.1990.tb03768.x
Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis
Abstract
1. Vasodilators are currently under investigation as possible therapeutic agents in the treatment of portal hypertension. Among them calcium-channel antagonists and organic nitrates have been of particular interest. Few and conflicting data, however, have been reported on their effect on liver function. 2. Twenty patients with biopsy-proven alcoholic cirrhosis were studied before and 25-35 min following the acute administration of 5 mg verapamil i.v. (eight patients) or 5 mg isosorbide dinitrate sublingually (12 patients). The plasma clearance of indocyanine green (ICG) and its intrinsic hepatic clearance were used as indices of liver function. Seven further patients were investigated before and after a placebo infusion according to the same methodology. 3. No significant change in ICG kinetics was found after verapamil or isosorbide dinitrate.
Similar articles
-
Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis.Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1221-5. doi: 10.1097/00042737-199911000-00006. Eur J Gastroenterol Hepatol. 1999. PMID: 10563530
-
Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with liver cirrhosis.J Hepatol. 1989 May;8(3):302-7. doi: 10.1016/0168-8278(89)90027-5. J Hepatol. 1989. PMID: 2732444
-
Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions.Gastroenterology. 1987 Sep;93(3):576-83. doi: 10.1016/0016-5085(87)90921-8. Gastroenterology. 1987. PMID: 3301517 Clinical Trial.
-
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.Eur Heart J. 1988 Feb;9(2):149-58. doi: 10.1093/oxfordjournals.eurheartj.a062468. Eur Heart J. 1988. PMID: 3280317 Review.
-
Clinical pharmacokinetics of organic nitrates.Clin Pharmacokinet. 1983 Sep-Oct;8(5):410-21. doi: 10.2165/00003088-198308050-00003. Clin Pharmacokinet. 1983. PMID: 6414751 Review.
Cited by
-
Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.Gut. 1995 Jan;36(1):104-9. doi: 10.1136/gut.36.1.104. Gut. 1995. PMID: 7890211 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.Clin Pharmacokinet. 1995 Nov;29(5):370-91. doi: 10.2165/00003088-199529050-00005. Clin Pharmacokinet. 1995. PMID: 8582120 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources